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Abstract
Background Patients with ulcerative colitis (UC) who
achieve remission with corticosteroids often relapse after
tapering or discontinuation; alternative treatments limiting
steroid exposure and UC relapse would be beneficial. It
remains uncertain whether patients with corticosteroid-in-
duced remission experience benefit with mesalamine
granules (MG), a locally acting aminosalicylate extended-
release capsule formulation for maintenance of UC
remission in adults.
Aims Efficacy and safety of MG 1.5 g once daily was
evaluated in patients with UC in corticosteroid-induced
remission.
Methods Data from patients with previous corticosteroid
use to achieve baseline UC remission were analyzed from
two 6-month randomized, double-blind, placebo-controlled
trials and a 24-month open-label extension (OLE). Six-
month relapse-free rates were assessed using the revised
Sutherland Disease Activity Index. UC-related adverse
events (AEs) were recorded during the 30 months.
Results Included were 158 steroid-treated patients in UC
remission (MG, n = 105; placebo, n = 53) and 74/105
MG-treated patients who continued MG in the OLE. A
significantly larger percentage of patients remained
relapse-free at 6 months with MG (77.1 %) versus placebo
(54.7 %; P = 0.006), with a 55 % reduction in relapse risk
(hazard ratio [HR] 0.45; 95 % CI 0.25–0.79). There was a
similar (49.2 %) reduction in risk of UC-related AEs at
6 months (HR 0.51; 95 % CI 0.31–0.84; P = 0.009) that
was sustained during the OLE.
Conclusions MG 1.5 g once daily administered for
maintenance of corticosteroid-induced remission was
associated with low risk of relapse and UC-related AEs.
ClinicalTrials.gov NCT00744016, NCT00767728, and
NCT00326209.
Keywords Inflammatory bowel diseases  Mesalamine 
Remission  Steroids  Ulcerative colitis
Introduction
Ulcerative colitis (UC) is a chronic, progressive gastroin-
testinal (GI) disease characterized by diffuse, uncontrolled
mucosal inflammation [1–3]. Its clinical course is charac-
terized by unpredictable periods of disease flare, and
remission [2]. The typical UC flare presents as a constel-
lation of symptoms, including rectal urgency, bloody
diarrhea, abdominal cramps, tenesmus, fatigue, and weight
loss [1–3]. The estimated incidence of UC in North
America ranges from 2.3 to 15.6 cases per 100,000 patient-
years, and the prevalence rate is 37.5–246 cases per
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100,000 individuals [4]. Notably, UC is associated with
substantial morbidity, disability, and economic burden,
with estimated annual costs approaching $2.7 billion in the
USA (measured in 2003–2004 US dollars) [2, 5, 6].
Oral 5-aminosalicylic acid (5-ASA) formulations are
considered first-line options for the induction and mainte-
nance of remission of mild-to-moderate UC [2]. Several
formulations have been developed to help improve patient
adherence (e.g., a formulation with reduced dosing fre-
quency) and to more directly target a higher concentration of
active agent to the colon. Mesalamine granules (MG), an
extended-release capsule formulation (Apriso; Salix
Pharmaceuticals, Inc., Raleigh, NC), is indicated for the
maintenance of UC remission in adults [7]. This formulation
combines a delayed- and extended-release delivery mecha-
nism [7, 8]. Specifically, each granule is designed to initiate
the release of mesalamine at a pH C 6, and the polymer
matrix facilitates a slow, sustained release of mesalamine in
the terminal ileum and throughout the colon. [8].
Two identically designed, double-blind, placebo-con-
trolled studies have demonstrated the efficacy of once-daily
MG (1.5 g/day) for the maintenance of UC remission, with
significantly more patients treated with MG remaining
relapse-free at 6 months compared with placebo in the
pooled analysis (79.4 vs. 62.4 %, respectively; P\ 0.001)
[9, 10].
Systemic corticosteroids may be administered for the
induction of remission in cases of acute relapse of UC,
especially when an oral 5-ASA is ineffective, or for
patients presenting with severe symptoms [2]. However,
the adverse effect profile of corticosteroids has led
healthcare providers to limit their use when possible and to
seek safer long-term alternatives. Furthermore, patients
with UC who achieve remission with corticosteroid treat-
ment often experience a relapse of symptoms during
tapering or soon after discontinuation [11]. Therefore, a
steroid-sparing therapy for the treatment of UC might aid
in reducing the burden of UC.
The purpose of this analysis was to evaluate the short-
and long-term efficacy and safety of once-daily MG in
patients who had previously received corticosteroid ther-
apy to achieve their UC remission. Patients in this analysis
participated in two randomized, double-blind, placebo-
controlled Phase 3 trials [9], including a cohort of these
patients who enrolled in a 24-month open-label extension
(OLE) trial [12].
Methods
Data were analyzed from three multicenter trials, including
two identically designed, randomized, double-blind,
6-month, placebo-controlled Phase 3 trials (MPUC3003
and MPUC3004) and a 24-month OLE trial (MPUC3005),
all of which were registered under ClinicalTrials.gov
identifiers NCT00744016, NCT00767728, and
NCT00326209, respectively [9, 12, 13]. Patient popula-
tions and study design for the three trials have been pre-
viously published and are briefly described in this
manuscript [9, 12]. All patients included in the current
analysis had a history of previous steroid use to achieve
their current UC remission and, upon enrollment, satisfied
the entry criteria for all studies as summarized below.
Patients enrolled in the OLE trial who were included in this
pooled analysis had been previously enrolled in one of the
double-blind trials.
Patients and Treatment
Male and non-pregnant, non-lactating female patients
C18 years of age were eligible for participation in the
double-blind trials if they had a confirmed diagnosis of
mild-to-moderate UC, determined using the revised
Sutherland Disease Activity Index (SDAI) [7, 14], with
defined subscale scores at screening (rectal bleeding score
of 0 and mucosal appearance score of 0 or 1). In addition,
all patients had a history of at least 1 flare requiring ther-
apeutic intervention within the past 1–12 months and were
documented to be in remission for [1 month but
\12 months. Primary exclusion criteria included receipt of
chronic immunosuppressive therapy or corticosteroids
(oral, rectal, intravenous) within 30 days prior to screening.
Forty-eight centers participated in trial MPUC3003, 40 in
MPUC3004, and 66 in MPUC3005. The double-blind trials
started in December 2004 and were completed by April or
August 2007; the OLE trial started in December 2005 and
was completed inMay 2008. Each protocol was approved by
institutional review boards or ethics committees and con-
ducted in accordance with International Conference on
Harmonisation guidelines and other applicable laws and
regulations. All patients provided written informed consent.
In the double-blind trials, patients were randomly
assigned to consecutive treatment numbers allocated in the
order of enrollment and in a 2:1 ratio received MG 1.5 g
(dosed as four capsules, each containing 0.375 g of
mesalamine) or matching placebo once daily. The use of
concomitant medications including immunosuppressants,
chronic non-steroidal anti-inflammatory drugs, cortico-
steroids, oral antibiotics (except as 7- to 10-day courses for
conditions unrelated to UC), psyllium-containing com-
pounds, and other 5-ASA formulations was prohibited in
the double-blind trials. The investigators, patients, and
research staff members (including project biostatisticians)
were blinded to study medication assignment until after
database lock at the end of each study. The OLE was
unblinded, and all patients received MG 1.5 g once daily.
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Assessments
The double-blind trials consisted of a 1-week screening
phase, a 6-month treatment phase, and a follow-up visit
(2 weeks after the end-of-treatment phase). The OLE trial
consisted of a 24-month treatment phase and a follow-up
visit 2 weeks after the last dose of MG. The 6-month
treatment phase of the double-blind, randomized trials
consisted of four clinic visits to assess disease activity and
monitor adverse events (AEs) at baseline and months 1, 3,
and 6. The 24-month OLE trial consisted of clinic visits to
monitor AEs at baseline, months 1, 3, and 6, and then every
3 months for up to 24 months. In addition, during the OLE
trial, telephone interviews were conducted at week 2,
months 2, 4, and 5, and then at every subsequent month
between clinic visits.
For the double-blind trials, a complete UC disease
activity assessment, including flexible sigmoidoscopy, was
performed at screening or baseline and at the 6-month visit
using the revised SDAI (all 4 components) [7, 14]. The
revision to the SDAI was the deletion of ‘‘friability’’ from a
mucosal appearance score equal to 1 to clarify the defini-
tion of remission. The revised SDAI total score evaluated
each of the following four parameters on a scale of 0–3,
with a maximum total score of 12: (1) stool frequency (i.e.,
0 to[ 4 stools/day more than normal); (2) rectal bleeding
(i.e., none to mostly blood); (3) mucosal appearance (i.e.,
intact mucosa with preserved or distorted vessels to blood
in lumen, gross ulceration, exudates), and (4) physician’s
rating of disease activity (i.e., normal to severe).
In the OLE trial, only patients entering the trial more
than 30 days after having completed the double-blind trial
were screened using the revised SDAI to confirm remis-
sion; for the remainder of patients, the baseline SDAI from
the end-of-treatment visit for the double-blind trial was
used. AEs were monitored throughout the three trials.
Endpoints and Data Analyses
Three populations of patients with a history of previous
corticosteroid use were analyzed: (1) the pooled intent-to-
treat (ITT) population, defined as randomized patients in
either of the double-blind trials who received at least one
dose of study medication and had a revised SDAI response
at the 6-month endpoint visit; (2) the short-term safety
population, defined as the ITT population with at least one
post-baseline safety assessment, and (3) the long-term
safety population, defined as patients who completed one
of the double-blind trials, received at least one dose of MG
during the OLE trial and had at least one post-baseline
safety assessment.
Demographics and baseline disease characteristics,
exposure, and safety data were summarized using
descriptive statistics. The primary efficacy endpoint during
the double-blind trials was the percentage of patients who
remained relapse-free from baseline through the 6-month
evaluation. Relapse was defined as a revised SDAI indi-
vidual component score for rectal bleeding of C1 and
mucosal appearance score C2, or early study termination
when the reason for termination was lack of efficacy or
discontinuation due to a UC-related AE. The treatment
groups were compared for the primary endpoint using a
Cochran–Mantel–Haenszel test.
Secondary efficacy endpoints included mean change
from baseline in the revised total SDAI score at the
6-month endpoint; change from baseline at month 6 in the
subcomponents of the SDAI score (rectal bleeding score,
mucosal appearance score, physician’s rating of disease
activity, and stool frequency); percentage of patients clas-
sified as achieving treatment success (defined as main-
taining an SDAI total score B2 with no individual
component[1 and a rectal bleeding score of 0 at month 6);
and the 6-month cumulative relapse-free probability.
Statistical analyses of the secondary endpoints were
performed in a predefined hierarchical fashion until a non-
significant P value was identified (P[ 0.05), after which
point significance tests were considered exploratory. For
relapse-free duration, a Cox proportional hazards regres-
sion model was used to assess differences between treat-
ment groups, a hazard ratio (HR) with associated 95 % CI
was generated to determine reduction in risk (1-HR) over
the first 6 months of treatment, and Kaplan–Meier methods
were used to calculate cumulative relapse-free probability
estimates.
Although no formal efficacy assessments were per-
formed in the OLE trial, the effects of MG on maintenance
of UC remission were assessed by evaluating UC-related
AEs, which were defined as UC, hematochezia, and fre-
quent bowel movements. The percentage of patients in the
short- and long-term safety populations who remained free
from UC-related AEs for the double-blind and OLE trials
was assessed from start of MG therapy through 6 and
30 months of therapy. UC-related, AE-free duration was
computed as the number of days between the start of MG
or placebo use (double-blind studies only), and the date on
which at least 1 of the predefined UC-related AEs was first
detected, or the date of early termination from the trial,
plus 1 day. Patients who completed 6 and 30 months of
treatment, or who withdrew from the trial without evidence
of a UC-related AE, were censored at the time of their final
evaluation; censoring time was calculated as the date of
final evaluation minus the start of study drug, plus 1 day.
For the short-term safety population, a Cox proportional
hazards regression model was used to assess differences in
UC-related, AE-free duration betweenMG and placebo. The
HR and associated 95 %CIwere obtained from thismodel to
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determine reduction in risk (1-HR) over the first 6 months of
treatment. Cumulative UC-related, AE-free probability
estimates were calculated using Kaplan–Meier methods.
Person-years of exposure (PYE) was calculated as
([mean exposure in days 7 365.25] 9 no. of patients).
PYE rate was calculated as (events 7 PYE). Mean percent
compliance was calculated using the following equation:
Results
Patients
A total of 158 of 562 patients (105 in MG group and 53 in
placebo group) from the two double-blind trials reported a
history of receiving corticosteroid therapy to induce UC
remission C30 days prior to enrollment and were included
in the ITT population and evaluation of the primary and
secondary efficacy endpoints (Fig. 1). Of these 158
patients, 154 (102 MG-treated and 52 placebo-treated
patients) were evaluated for UC-related AE events during
6 months of treatment (short-term safety population); four
patients were excluded because post-baseline safety data
were not available. Seventy-four of the 102 (72.5 %) MG-
treated patients entered the OLE trial and were evaluated
for UC-related AEs during an additional 24 months of
therapy (months 6–30; long-term safety population).
Demographic and baseline disease characteristics were
similar between the pooled ITT and short- and long-term
safety populations (Table 1). Overall, the three cohorts of
patients were predominantly white ([92 %) and in their
mid-40s (45–48 years), with a slight female predominance.
The mean duration of current UC remission was approxi-
mately 17–18 weeks, and mean baseline total SDAI scores
were approximately 0.7–0.9.
Adherence to once-daily MG was high among the safety
populations analyzed, with mean adherence of approxi-
mately 96 % during the 6-month double-blind and OLE
trials. Mean exposure to MG was 436 and 623 days in the
short- and long-term safety populations, respectively, and
the mean total cumulative MG dose was 630 and 900 g,
respectively.
Efficacy
For the pooled ITT population of patients previously treated
with corticosteroids, a significantly higher percentage of
patients treated with MG 1.5 g were relapse-free at month 6
compared with placebo (77.1 vs. 54.7 %; P = 0.006). Dur-
ing the 6-month period, treatment with MG reduced the risk
of relapse by 55 % versus placebo in patients who were
previously treated with corticosteroids (HR 0.45; 95 % CI
0.25–0.79; Fig. 2). Significant improvements (P B 0.025)
favoring MG once daily were also observed for most sec-
ondary efficacy endpoints, including improvement in mean
total SDAI score, rectal bleeding score, physician’s disease
activity rating score, and stool frequency score (Table 2).
Adverse Events
UC-Related Adverse Events
Among patients previously treated with corticosteroids in
the short-term safety population, a greater percentage of
patients receiving MG for 6 months (79.4 %) had not
Fig. 1 Patient disposition for subpopulation of patients previously
treated with corticosteroids for induction or maintenance of remission
of ulcerative colitis during the two double-blind Phase 3 trials
(MPUC3003 and MPUC3004) and the open-label extension trial
(MPUC3005). MG mesalamine granules, OLE open-label extension.
aSafety data not available for 4 patients (3 in the MG group and 1 in
the placebo group)
% compliance ¼ no: of pillsdispensed no: of pills returnedð Þð4 no: of days of exposureÞ  100
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reported UC-related AEs compared with patients receiving
placebo for 6 months (67.3 %). During the 6-month period,
treatment with MG resulted in a 49.2 % reduction in the
risk of a UC-related AE versus placebo in patients who
were previously treated with corticosteroids (HR 0.51;
95 % CI 0.31–0.84; P = 0.009).
For the 74 MG-treated patients who received an addi-
tional 24 months of therapy, only 12 (16.2 %) experienced
a GI-related AE (14 events total), with the majority of the
12 patients (91.7 %) reporting UC. Patients in the long-
term safety population treated with MG for up to
30 months had a statistically significantly greater proba-
bility of remaining free from UC-related AEs compared
with patients treated with placebo for 6 months in the
double-blind studies (P = 0.0001; Fig. 3).
Overall Adverse Events
The incidence of any treatment-emergent AEs among
patients previously treated with corticosteroids was low for
patients treated for up to 6 months (short-term safety popu-
lation) with MG or placebo (Table 3). When comparing the
short- and long-term safety populations following MG
therapy, the rate of any AE, based on PYE, was higher in
patients treated with long-term compared with short-term
exposure (9.6 vs. 6.0 events/PYE, respectively). However,
overall drug-related AE rates (0.5 events/PYE) and rates of
AEs leading to premature discontinuation from the study (0.4
events/PYE for patients with short-term exposure vs. 0.3
events/PYE for patients with long-term exposure) were
similar between the two MG safety populations. Likewise,
the rate of GI-related AEs for the MG treatment groups was
comparable between patients in the short- and long-term
safety populations (Table 3). Headache was the most com-
mon non-GI-related AE reported among MG patients fol-
lowing short- and long-term administration (rates of 0.6 and
1.0 events/PYE, respectively). Renal- and hepatic-related
Fig. 2 Probability of remaining relapse-free during 6 months of
treatment in patients previously treated with corticosteroids
(MPUC3003 and MPUC3004, pooled). P value determined using
Poisson regression analysis. MG mesalamine granules
Table 1 Demographics and baseline characteristics of patients previously treated with corticosteroids for ulcerative colitis
Parameter ITT populationa (N = 158) Long-term safety
populationa (N = 74)
MG 1.5 g/day
(n = 105)
Placebo (n = 53) MG 1.5 g/day (n = 74)
Age, year, mean (SD) 45.3 (14.1) 48.3 (15.4) 47.9 (13.3)
Sex, n (%)
Male 48 (45.7) 24 (45.3) 32 (43.2)
Female 57 (54.3) 29 (54.7) 42 (56.8)
Race, n (%)
White 97 (92.4) 49 (92.5) 71 (95.9)
Black 7 (6.7) 3 (5.7) 3 (4.1)
Other 2 (1.9) 1 (1.9) 0
UC duration, week, median (range) 180.0 (14.0–2049.0) 160.0 (17.0–2151.0) 175.5 (14.0–2049.0)
Duration of current UC remission, week, mean (SD) 17.4 (11.7) 17.0 (11.6) 18.4 (12.3)
Revised SDAI score, mean (SD)
Total 0.8 (0.9) 0.9 (1.0) 0.7 (0.8)
Stool frequency 0.1 (0.4) 0.1 (0.4) 0.1 (0.4)
Rectal bleeding 0 0.0 (0.1) 0
Mucosal appearance 0.5 (0.5) 0.6 (0.5) 0.5 (0.5)
Physician’s rating of severity 0.2 (0.4) 0.2 (0.4) 0.2 (0.4)
ITT intent-to-treat, MG mesalamine granules, SDAI Sutherland Disease Activity Index, UC ulcerative colitis
a Data obtained at baseline for Phase 3 double-blind trials
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AEs were relatively uncommon (\5 %) in patients previ-
ously treated with corticosteroids receiving MG 1.5 g once
daily for up to 30 months.
Discussion
In this pooled analysis, MG administered once daily pro-
vided long-term protection against relapse and UC-related
AEs for up to 30 months (the duration of the studies) in
patients previously induced into remission with cortico-
steroid therapy for UC flares. These findings are compa-
rable to the results from the overall population of the two
double-blind trials (which included the corticosteroid
population assessed in the current analysis), wherein the
UC relapse-free rate at 6 months was significantly higher
in patients treated with MG compared with placebo (79.4
vs. 62.4 %, respectively; P\ 0.001) [9, 10]. In the current
analysis at 6 months, patients previously treated with
corticosteroids also experienced a significantly higher
relapse-free rate in the MG group (77.1 %) compared with
placebo (54.7 %; P = 0.006), supporting MG as being
efficacious in maintaining UC remission in this patient
population.
Fig. 3 Probability of remaining free from ulcerative colitis (UC)-
related adverse events (AEs; defined as UC, hematochezia, or
frequent bowel movements) during short-term treatment (MPUC3003
and MPUC3004, pooled) and long-term treatment (MPUC3005). MG
mesalamine granules
Table 2 Secondary efficacy endpoints at month 6a for patients previously treated with corticosteroids for ulcerative colitis (ITT population)
Endpoint MG 1.5 g/day (n = 105) Placebo (n = 53) P value
Change from baseline in revised total SDAI score, mean (SD) 0.9 (2.4) 2.2 (3.0) 0.005
Change from baseline in stool frequency, n (%)
-1 5 (4.8) 1 (1.9) 0.003
0 80 (76.2) 30 (56.6)
1 10 (9.5) 11 (20.8)
2 9 (8.6) 6 (11.3)
3 1 (1.0) 5 (9.4)
Change from baseline in rectal bleeding score, n (%)
0 85 (81.0) 34 (64.2) 0.025
1 12 (11.4) 10 (18.9)
2 7 (6.7) 8 (15.1)
3 1 (1.0) 1 (1.9)
Change from baseline in mucosal appearance, n (%)
-1 16 (15.2) 4 (7.5) 0.056
0 66 (62.9) 29 (54.7)
1 12 (11.4) 14 (26.4)
2 11 (10.5) 6 (11.3)
3 0 0
Change from baseline in physician’s rating of disease, n (%)
-1 7 (6.7) 1 (1.9) 0.008
0 77 (73.3) 32 (60.4)
1 15 (14.3) 10 (18.9)
2 5 (4.8) 10 (18.9)
3 1 (1.0) 0
Maintenance of SDAI B2 with no individual component[1
and rectal bleeding = 0, n (%)
77 (73.3) 27 (50.9) 0.009
Cumulative relapse-free probability (SE) 0.76 (0.04) 0.52 (0.07) 0.005
ITT intent-to-treat, MG mesalamine granules, SDAI Sutherland Disease Activity Index, SE standard error
a Month 6 = end of 1 treatment in Phase 3 double-blind treatment phase
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Although relapse-free rates were not prospectively
assessed throughout the course of the long-term OLE trial
(e.g., using the SDAI), monitoring of UC-related AEs in
patients previously treated with corticosteroids provided
further evidence of the short- and long-term benefits of
MG. In this pooled analysis, the lower rate of UC-related
AEs with MG versus placebo during the 6-month, double-
blind treatment period was sustained in patients continuing
to receive MG once daily for up to 30 months. Thus,
consideration of UC-related AE rates over time may offer a
long-term surrogate for assessing the potential benefit of
MG.
It is noteworthy that, for the 74 MG-treated patients in
the long-term safety population and the 102 MG-treated
patients in the short-term population, the reported inci-
dence of a UC flare AE was similar (14.9 and 17.6 %,
respectively), with both incidences nearly half the repor-
ted incidence observed in the placebo-treated ITT popu-
lation (30.8 %). Further examination of UC flare AE rates
based on PYE revealed a low rate (0.3 events/PYE) after
MG treatment for up to 30 months, which was
approximately one-third the rate observed in patients
receiving placebo (1.1 events/PYE) in the double-blind
trials.
This analysis also demonstrated that MG was well tol-
erated for up to 30 months in patients with UC who had
received prior corticosteroid therapy. The percentage of
patients treated with MG 1.5 g once daily with a drug-
related AE in the long-term safety population was similar
to that observed in the short-term safety population (both
10.8 %), and comparable to findings from the overall study
population in the original double-blind trials (10.6 %).
Headache was the only non-GI-related AE reported in
[10 % of MG-treated patients, (11.8 and 13.5 % of
patients in short- and long-term safety populations,
respectively). Hepatic and renal system-related AEs were
infrequently observed with long-term MG use. Overall,
results were similar to those observed in the overall pop-
ulation of the two double-blind trials [9], as well as other
trials of MG for maintenance and remission of UC [10, 15].
Safety results for MG from this study also were consistent
with those reported for the OLE (long-term) study, in that
Table 3 Overall AE summary of patients previously treated with corticosteroids for ulcerative colitis during the double-blind and open-label
extension trials
Adverse events, % (ratea) Short-term safety population (N = 154) Long-term safety population
MG 1.5 g/day (N = 74)
PYEb = 33.4cMG 1.5 g/day (n = 102)
PYEb = 40.2
Placebo (n = 52)
PYEb = 16.1
Any AE 65.7 (6.0) 65.4 (5.8) 81.1 (9.6)
Serious AEs 2.9 (0.1) 1.9 (0.1) 10.8 (0.3)
Drug-related AEs 10.8 (0.5) 9.6 (0.4) 10.8 (0.5)
AEs leading to discontinuation 16.7 (0.4) 13.5 (0.4) 12.2 (0.3)
Deaths 0 0 0
AEs reported in[5 % of
MG-treated patients, % (ratea)
Headache 11.8 (0.6) 5.8 (0.2) 13.5 (1.0)
Diarrhea 7.8 (0.4) 5.8 (0.3) 9.5 (0.5)
Upper abdominal pain 5.9 (0.3) 0 6.8 (0.5)
Ulcerative colitis 17.6 (0.5) 30.8 (1.1) 14.9 (0.3)
Influenza 5.9 (0.2) 1.9 (0.1) 9.5 (0.3)
Upper respiratory tract infection 3.9 (0.2) 0 8.1 (0.3)
Sinusitis 2.9 (0.1) 1.9 (0.2) 8.1 (0.2)
Abdominal pain 6.9 (0.2) 11.5 (0.4) 8.1 (0.3)
Constipation 6.9 (0.2) 1.9 (0.1) 8.1 (0.2)
Nasopharyngitis 0 3.8 (0.1) 8.1 (0.2)
Viral respiratory tract infection 1.0 (0) 0 8.1 (0.2)
Nausea 5.9 (0.2) 1.9 (0.1) 6.8 (0.2)
Loose stools 1.0 (0) 5.8 (0.6) 5.4 (0.1)
Insomnia 2.9 (0.1) 0 5.4 (0.1)
AE adverse event, MG mesalamine granules
a Rate = events 7 PYE
b PYE = person-years of exposure ([mean exposure in days 7 365.25] 9 no. of patients)
c Data reflect AEs during time in open-label extension
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some AEs occurred early after starting therapy and
decreased over time [12].
The role of systemic corticosteroids in the management
of UC continues to evolve, although these drugs are typi-
cally reserved for inducing remission in patients who are
refractory to oral 5-ASAs in combination with topical
therapy, or for patients with moderate-to-severe symptoms
who require rapid improvement [2]. Despite their benefits,
it is widely recognized that prolonged use of systemic
corticosteroids may expose patients to potential toxicities
and occasionally result in severe complications. These
complications may include cushingoid features, metabolic
disturbances, emotional and psychiatric disturbances,
opportunistic infections, impaired wound healing, striae,
glaucoma, cataracts, and osteoporosis [2, 16, 17].
Accordingly, to minimize the risk of steroid-induced AEs
in patients with UC, it is recommended that corticosteroid
administration be restricted to short-term use only and at
the lowest possible effective dose [17].
Another dilemma with corticosteroid use in UC
patients is the highly recognized ‘‘rebound effect’’ that
often occurs following tapering or discontinuation when
switching to alternative therapies [11]. As such, there is
a need for agents to be identified that may minimize or
prevent steroid-induced UC rebound, prolong the dura-
tion of remission, and reduce the need for future sys-
temic corticosteroid therapy, especially for patients with
moderate-to-severe disease. The current data from this
study support MG administration for the long-term
maintenance of UC remission in a population of patients
previously treated with corticosteroids to induce
remission.
The lack of objective response measurements (SDAI),
the lack of availability of placebo-controlled data after
6 months, and the small patient population assessed
during the OLE trial (long-term population) were limi-
tations of this study. In addition, conclusions suggesting
the role of MG in steroid switching or tapering cannot
be decisively drawn from this post hoc analysis because
patients did not immediately switch or taper corticos-
teroid therapy and begin MG or placebo therapy in the
current study. One eligibility requirement for both dou-
ble-blind trials was that patients were not permitted to
use corticosteroids within 30 days of screening. In
addition, as patients were in UC remission at enrollment,
initial disease severity scores prior to use of steroid
therapy were not available. Thus, disease severity at the
time of steroid-treated UC flare (i.e., mild versus mod-
erate) could have theoretically impacted maintenance of
remission during treatment. Therefore, the results from
this study are considered exploratory and need validation
with prospective trials, and the generalizability of these
findings should be further explored.
In conclusion, this pooled post hoc analysis demon-
strated that MG provides long-term (up to 30 months)
maintenance of UC remission in patients with a history of
prior corticosteroid therapy for UC flares or maintenance of
UC remission. Accordingly, treatment with once-daily MG
may allow for avoidance of or reduction in corticosteroid
use in the maintenance of remission for patients with
moderate-to-severe UC. Future large, well-designed,
prospective clinical trials are necessary to fully validate
these initial observations suggesting that there is long-term
benefit with using MG for maintenance of remission in
patients with UC who received corticosteroids to induce
remission.
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